中國同輻股份有限公司 China Isotope & Radiation Corporation （於中華人民共和國註冊成立的股份有限公司） (A joint stock company incorporated in the People's Republic of China with limited liability) 股份代號 Stock Code：1763 2024 年度報告 ANNUAL REPORT 目 錄 CONTENTS | 公司簡介 | | | --- | --- | | Corporate Profile | 2 | | 公司資料 | | | Corporate Information | 4 | | 釋義 | | | Definitions | 10 | | 主席報告 | | | Chairman's Statement | 14 | | 要事一覽 | | | Highlights of the Year | 18 | | 核技術應用行業發展情況 | | | Development Status of the Nuclear Technology | | | Application ...

本公司综合考虑了历史因素、市场条件、资源条件及中核集团"整体•协同"的要求，订立《增资协 议》，引入战略投资者筹集资金，所募集资金将全部用于补充四川同源放射源研发生产基地项目的项目 建设及经营资金，有利于四川同源保持合理的资产负债结构。 同时，订立《增资协议》，有助于利用股东各自研发和生产优势，实现资源共享，加速推动放射源原料 国产化，为四川同源构建稳定的原料供应渠道，有助于发挥四〇四成都及成都核总的产业协同发展效 应，符合本公司及股东的整体利益。 智通财经APP讯，中国同辐(01763)发布公告，本公司附属公司中核高通于2025年3月28日与四〇四成 都、成都核总及四川同源订立《增资协议》。四〇四成都及成都核总同意以货币进行出资，对中核高通 全资附属公司四川同源分别增资人民币1234.57万元及人民币1111.11万元。增资完成后，四川同源的注 册资本将由人民币1亿元增加至人民币1.23亿元，中核高通、四〇四成都及成都核总将分别持有四川同 源81%、10%及9%的股权，四川同源将仍为中核高通(本公司附属公司)的附属公司。 四川同源成立于2019年5月，是由中核高通出资建设的对标国际一流的放射源研发生产基地。 ...

香港交易及結算有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該 等內容而引致之任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 截至2024年12月31日止年度業績公告 年度業績 中國同輻股份有限公司（「本公司」或「中國同輻」，連同附屬公司統稱「本集團」或 「我們」）董事（「董事」）會（「董事會」）謹此提呈本集團截至2024年12月31日止年度 （「2024年」或「報告期」）之經本公司核數師信永中和（香港）會計師事務所有限公 司完成審核的合併財務報表，連同2023年同期之比較數字載列如下： 1 截至2024年12月31日止年度之合併損益表 以人民幣（「人民幣」）列值） | | | 2024年 | 2023年 | | --- | --- | --- | --- | | | 附註 | 人民幣千元 | 人民幣千元 | | 收益 | 4 | 7,574,756 | 6,634, ...

88ENNE 中期報告 2024 Interim Report 中國同輻股份有限公司 China Isotope & Radiation Corporation （於中華人民共和國註冊成立的股份有限公司） (A joint stock company incorporated in the People's Republic of China with limited liability) 股份代號 Stock Code：1763 注射用亚缘亚甲基二路B C =7 == 2024 中期報告 Interim Report 目 錄 公司資料 2 財務摘要 4 集團簡介 5 管理層討論與分析 6 企業管治報告及其他資料 32 簡明合併中期財務資料之審閱報告 38 簡明合併損益表 39 簡明合併損益及其他全面收入表 40 簡明合併財務狀況表 41 簡明合併權益變動表 43 簡明合併現金流量表 45 簡明合併中期財務報告附註 46 釋義 69 2 中國同輻股份有限公司 公司資料 | --- | --- | |------------------------------------------------------|- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763) 截至2024年6月30日止六個月之中期業績公告 業績摘要 中國同輻股份有限公司（「本公司」或「中國同輻」，連同附屬公司統稱「本集團」或 「我們」）董事（「董事」）會（「董事會」）謹此提呈本集團截至2024年6月30日止六個 月（「2024年上半年」或「報告期」）之未經審核簡明合併財務報表，連同2023年同 期未經審核之比較數字載列如下： 1 簡明合併損益表 截至2024年6月30日止六個月 | --- | --- | --- | --- | |------------------------------------------------------------------------------------------|-------|- ...

Financial Performance - Revenue for the year ended December 31, 2023, was RMB 6,634,992 thousand, representing an increase from RMB 6,153,549 thousand in 2022, a growth of approximately 7.8%[8] - Gross profit for 2023 was RMB 3,482,239 thousand, with a gross margin of 52.5%, down from a gross margin of 57.2% in 2022[8] - Operating profit increased to RMB 941,598 thousand, with an operating profit margin of 14.2%, compared to 14.9% in the previous year[8] - Net profit attributable to equity shareholders was RMB 370,967 thousand, with basic earnings per share of RMB 1.16, down from RMB 1.23 in 2022[8] - The net profit for the year was RMB 778 million, reflecting a year-on-year increase of 2.8%[23] - The company reported a total asset value of RMB 13.19 billion and a net asset value of RMB 7.14 billion, with a debt-to-asset ratio of 45.9%[23] - The company’s net profit attributable to shareholders was RMB 371 million, which represents a year-on-year decline of 5.43%[23] - Revenue increased by 7.82% from RMB 6,153.5 million in 2022 to RMB 6,635.0 million in 2023, driven by growth in pharmaceuticals and radiation therapy equipment[101] - Sales cost rose by 19.6% from RMB 2,635.9 million in 2022 to RMB 3,152.8 million in 2023, primarily due to increased costs in radiation therapy equipment and related services[102] - Gross profit decreased by 1.0% from RMB 3,517.7 million in 2022 to RMB 3,482.2 million in 2023, with gross margin declining from 57.2% to 52.5%[102] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 13,191,710 thousand, an increase from RMB 11,789,723 thousand in 2022[8] - Total liabilities increased to RMB 6,052,382 thousand from RMB 5,180,115 thousand in 2022[8] - Current assets increased by 8.7% from RMB 7,543.8 million in 2022 to RMB 8,194.5 million in 2023, with a notable rise in trade receivables[117] - Current asset net worth grew by 12.2% from RMB 3,512.4 million in 2022 to RMB 3,940.5 million in 2023[117] - Trade and other receivables amounted to RMB 4,130.9 million, with a provision for bad debts of RMB 217.82 million[120] - Trade and other payables totaled RMB 3,882.6 million as of December 31, 2023[121] - The total bank loans of the group reached RMB 1,570.37 million as of December 31, 2023[122] Research and Development - Research and development investment intensity exceeded 9%, with nearly 300 patents applied for, marking a 55% increase year-on-year[14] - The company has multiple radiopharmaceuticals in various stages of research and development, including [18F] sodium fluoride injection, which has completed clinical trials and submitted for market registration[41] - The [131I]-MIBG injection for diagnosing neuroendocrine tumors is currently undergoing Phase III clinical trials[43] - The company has filed 298 patent applications and received 240 patent grants, enhancing its technological capabilities[47] - The company has 945 valid patents, including 149 invention patents, reflecting its strong R&D capabilities[47] Market and Segment Performance - The company generated 62.2% of its revenue and 83.0% of its gross profit from the pharmaceutical segment, indicating a strong reliance on this high-potential industry[11] - The pharmaceutical segment achieved revenue of RMB 4,128.6 million, a year-on-year increase of 5.2%[26] - Revenue from diagnostic and therapeutic radioactive drugs reached RMB 1,682.8 million, up 15.3% year-on-year[26] - The breath testing segment generated revenue of RMB 2,323.8 million, a decline of 1.0% year-on-year[26] - The radiation source products segment reported revenue of RMB 586.2 million, a year-on-year increase of 0.9%[28] - The nuclear medical equipment and related services segment saw revenue of RMB 933.7 million, a significant increase of 27.5% year-on-year[33] - The trade services and other businesses generated revenue of RMB 815.7 million, reflecting a year-on-year growth of 9.3%[36] Strategic Initiatives and Collaborations - The company plans to leverage its collaboration with China National Nuclear Corporation to enhance its capabilities in isotope and radiopharmaceutical applications[11] - Future market demand for nuclear technology applications is expected to grow, providing broader development opportunities for the company[10] - The company accelerated the development of the "One County, One Specialty" initiative in collaboration with the Wu Jieping Medical Foundation[17] - The company has established a technology innovation committee to enhance its innovation-driven development strategy[18] - The company is focusing on the domestic Lu-177 and Ge/Ga generator markets to establish a foundation for future growth in 2024[39] - The company is actively expanding its market presence through various academic and promotional events, enhancing its brand recognition[38] Corporate Governance and Management - The board confirmed that there were no significant adverse changes in the financial and operational conditions as of December 31, 2023[139] - The board consists of 11 members, including 3 executive directors and 4 independent non-executive directors, ensuring a balanced composition for effective decision-making[166] - The company has adopted the principles and code provisions of the Corporate Governance Code as its governance framework[160] - The board regularly reviews the contributions of directors to ensure they fulfill their responsibilities adequately[165] - The company has established six committees, including the Audit and Risk Management Committee and the Strategic Committee, to oversee specific aspects of the company's affairs[186] Future Outlook - In 2024, the company aims to achieve new highs in operating revenue and net profit, focusing on maintaining strong growth momentum[83] - The company plans to accelerate the construction of six major bases in North China, East China, and Sichuan to enhance its industry control capabilities[83] - The company aims to improve management efficiency through digital transformation and the establishment of smart factory projects[87] - The company recognizes the "14th Five-Year Plan" as a strategic opportunity period for the nuclear technology application industry and is committed to achieving its key tasks[90]

Financial Performance - For the year ended December 31, 2023, the total revenue was RMB 6,634,992 thousand, an increase of 7.8% compared to RMB 6,153,549 thousand in 2022[2] - The gross profit for 2023 was RMB 3,482,239 thousand, slightly down from RMB 3,517,682 thousand in 2022, resulting in a gross margin of approximately 52.5%[2] - Operating profit increased to RMB 941,598 thousand in 2023, up from RMB 913,963 thousand in 2022, reflecting a growth of 3.0%[2] - The net profit for the year was RMB 776,130 thousand, representing a 2.8% increase from RMB 755,237 thousand in 2022[2] - Basic and diluted earnings per share for 2023 were RMB 1.16, compared to RMB 1.23 in 2022, indicating a decrease of 5.7%[2] - Total comprehensive income for the year was RMB 770,324 thousand, slightly up from RMB 767,386 thousand in 2022[4] Assets and Liabilities - Non-current assets as of December 31, 2023, amounted to RMB 3,601,172 thousand, an increase from RMB 2,939,823 thousand in 2022[5] - Current assets increased to RMB 4,997,241 thousand in 2023 from RMB 4,245,880 thousand in 2022, showing a growth of 17.7%[5] - Total liabilities as of December 31, 2023, were RMB 8,194,469 thousand, compared to RMB 7,543,843 thousand in 2022, reflecting an increase of 8.7%[5] - The company's equity attributable to shareholders was RMB 4,693,320 thousand as of December 31, 2023, up from RMB 4,468,659 thousand in 2022, indicating a growth of 5.0%[6] Revenue Breakdown - Pharmaceutical sales generated RMB 4,017,476 thousand in 2023, up from RMB 3,880,262 thousand in 2022, reflecting a growth of 3.5%[16] - Revenue from medical devices surged to RMB 544,690 thousand in 2023, compared to RMB 171,843 thousand in 2022, marking a significant increase of 216.5%[16] - The report indicates that external customer revenue for the radiation therapy equipment and related services segment was RMB 706,406 thousand in 2023, compared to RMB 514,012 thousand in 2022, representing a growth of 37.5%[22] - Revenue from the sale of subsidiaries amounted to RMB 158,435 thousand in 2023, with no comparable figure in 2022[25] Expenses and Costs - Employee costs rose to RMB 867.378 million in 2023, up from RMB 797.833 million in 2022, reflecting an increase of 8.69%[27] - Depreciation expenses increased to RMB 237.104 million for property, plant, and equipment, compared to RMB 204.937 million in 2022, marking a growth of 15.66%[28] - Sales cost rose by 19.6% from RMB 2,635.9 million in 2022 to RMB 3,152.8 million in 2023, primarily due to increased costs in radiation therapy equipment and related services[79] - Administrative expenses, R&D costs, and credit impairment losses increased by 11.7% from RMB 906.9 million in 2022 to RMB 1,013.2 million in 2023, representing 15.3% of revenue[82] Strategic Acquisitions and Partnerships - The company acquired 100% equity of Dalian China Nuclear Radiation Technology Co., Ltd. for a total consideration of RMB 4,611,000[9] - The company is focused on expanding its market presence through strategic acquisitions and partnerships in the radiation technology sector[9] - The company signed agreements to acquire two enterprises with a total investment amount of RMB 103.4087 million, including Dalian CNNC Radiation Technology Co., Ltd. for RMB 4.6105 million and Xi'an Zhanshi Testing Engineering Co., Ltd. for RMB 98.7982 million[56] Research and Development - The company has multiple radiopharmaceuticals in various stages of research and development, including the completion of clinical trials for Fluorine-18 Sodium Injection and ongoing Phase III trials for Iodine-131 MIBG Injection[47] - The company has received clinical trial approval for Fluorine-18 Beta-Amyloid Injection, which is being developed for early diagnosis of Alzheimer's disease and is currently in Phase I trials[49] - The company has established research cooperation with several prestigious institutions, including the Chinese Academy of Sciences and Harbin Institute of Technology, to enhance academic exchange and talent cultivation[54] Market Expansion and International Presence - The company is actively expanding its international market presence, successfully signing a nuclear medicine project in Indonesia and winning a large foreign aid medical project in Uzbekistan[55] - The company is focusing on the domestic Lu-177 and Ge/Ga generator market to establish a foundation for market expansion in 2024[46] Corporate Governance and Compliance - The group has adopted a corporate governance code and has complied with its mandatory provisions throughout the reporting period[102] - The audit and risk management committee reviewed and confirmed the group's consolidated financial performance for the year ended December 31, 2023[104] Future Outlook - In 2024, the company aims to achieve new highs in operating revenue and net profit, focusing on maintaining strong growth momentum[67] - The company is committed to deepening reforms to release innovation vitality and development potential, with a focus on strategic emerging industries[68]

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 2,740.6 million, an increase of 4.6% from RMB 2,619.6 million for the same period in 2022[6] - Gross profit for the same period was RMB 1,484.8 million, with a gross margin of 54.2%, down from 58.5% in the previous year[6] - Operating profit increased to RMB 340.8 million, maintaining an operating profit margin of 12.4%[6] - Profit attributable to equity shareholders was RMB 126.9 million, representing a 13.8% increase from RMB 112.0 million in the prior year[6] - Net profit for the same period was RMB 283.7 million, representing a year-on-year growth of 17.9%[10] - Revenue from the pharmaceutical segment reached RMB 1,787.8 million, up 1.3% year-on-year, with diagnostic and therapeutic radioactive drugs contributing RMB 816.6 million, a 15.9% increase[12] - Revenue from radiation therapy equipment and related services surged to RMB 402.1 million, marking a 49.3% increase compared to the previous year[15] - Revenue increased by 4.6% from RMB 2,619.6 million to RMB 2,740.6 million, driven by significant growth in the radiation source and radiation therapy equipment segments[45] Assets and Liabilities - Total assets as of June 30, 2023, were RMB 11,796.8 million, compared to RMB 11,686.6 million at the end of 2022[7] - Total liabilities increased to RMB 5,301.3 million from RMB 5,133.1 million at the end of 2022[7] - Current assets decreased by 4.0% from RMB 3,524.9 million to RMB 3,383.2 million, mainly due to a reduction in cash and cash equivalents[55] - Trade receivables and other receivables amounted to RMB 4,379.9 million, with a provision for bad debts of RMB 207.9 million as of June 30, 2023[60] - Trade and other payables totaled RMB 3,812.2 million as of June 30, 2023[61] - As of June 30, 2023, the total bank loans of the group amounted to RMB 946.7 million[62] Market Position and Strategy - The company generated 65.23% of its revenue and 84.55% of its gross profit from the pharmaceutical segment, indicating a strong focus on nuclear medicine[8] - The company is positioned as a leading manufacturer in the domestic market for diagnostic and therapeutic radioactive pharmaceuticals, with significant market potential[8] - Future market demand for nuclear technology applications is expected to grow, driven by economic development and improved living standards in China[8] - The company plans to leverage its collaboration with China National Nuclear Corporation to enhance its service offerings and market reach[8] - The company is actively expanding its market presence through strategic collaborations and product integration in the radioactive pharmaceuticals sector[11] - The company is focusing on enhancing its academic brand in respiratory testing products and promoting health management knowledge nationwide[11] Research and Development - The company has established a special fund for smart nuclear medicine in collaboration with the Wu Jieping Medical Foundation, aiming to create integrated solutions in the nuclear medicine field[18] - As of June 30, 2023, the company has multiple radiopharmaceuticals in various stages of development, including [18F] sodium fluoride injection, which has completed clinical trials and submitted for market registration[19] - The company is conducting a Phase III clinical trial for [131I]-MIBG injection, which is used for diagnosing neuroendocrine tumors[20] - The company has received approval for clinical trials of [18F] Florastamin injection, a promising prostate cancer diagnostic drug, in March 2023[20] - The company is advancing the development of [103Pd] sealed seed sources for prostate cancer treatment, having completed all preclinical research[22] - The company is actively promoting the standardization of nuclear medicine treatment guidelines and the establishment of more demonstration bases in Zhejiang Province[18] Operational Efficiency - The company aims to achieve new highs in operating income and net profit for the full year of 2023, driven by favorable macroeconomic conditions and technological innovation[34] - The company is committed to enhancing its internal management systems to support its international operations and improve economic efficiency[29] - The company is focusing on enhancing its core competitiveness through innovation-driven development and has established a Science and Technology Innovation Committee to lead these efforts[32] - The company has achieved significant progress in the construction of its isotope production base, which will become the largest in the country upon completion[31] Financial Management - The company has sufficient cash reserves and committed funding from major financial institutions to meet short-term and long-term liquidity needs[67] - The group has established policies to monitor credit risk continuously, focusing on the credit quality of new customers before accepting credit requests[66] - The company is actively monitoring market risks, including foreign exchange and liquidity risks, to ensure financial stability[39][41] - The company will continue to strengthen its compliance system and improve risk management efficiency to mitigate operational risks[42] Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2023[69] - The company has a total share capital of RMB 319,874,900, consisting of 79,968,800 H shares and 239,906,100 domestic shares[82] - As of June 30, 2023, the major shareholder China National Nuclear Corporation holds 236,150,233 shares, representing 98.43% of the beneficial ownership in domestic shares[85] - The total beneficial ownership of China National Nuclear Corporation and its subsidiaries in domestic shares is approximately 98.43%[86] Employee and Operational Metrics - Employee costs for the six months ended June 30, 2023, were approximately RMB 357.6 million, a decrease from RMB 485.9 million for the same period in 2022[73] - The company employed 3,264 employees as of June 30, 2023, compared to 3,244 employees as of June 30, 2022[73] - The company’s employee compensation policy aims to incentivize and retain talented employees to achieve long-term corporate goals[73]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中 國 同 輻 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 截至2023年6月30日止六個月之中期業績公告 業績摘要 中國同輻股份有限公司（「本公司」或「中國同輻」，連同附屬公司統稱「本集團」或 「我們」）董事（「董事」）會（「董事會」）謹此提呈本集團截至2023年6月30日止六個 月（「2023年上半年」或「報告期」）之未經審核簡明合併財務報表，連同2022年同 期未經審核之比較數字載列如下： ...

Financial Performance - Revenue for the year ended December 31, 2022, was RMB 6,146,172,000, an increase of 19.5% from RMB 5,143,694,000 in 2021[8] - Gross profit for 2022 was RMB 3,514,679,000, with a gross margin of 57.2%, down from 63.0% in 2021[8] - Operating profit increased to RMB 912,744,000, representing an operating margin of 14.9%[8] - Net profit attributable to equity shareholders was RMB 391,605,000, with a net profit margin of 12.3%, compared to 13.1% in the previous year[8] - Total profit reached RMB 921 million, with a year-on-year increase of 14.68%[15] - Net profit amounted to RMB 755 million, reflecting a year-on-year growth of 12.11%[15] - Revenue increased by 19.5% from RMB 5,143.7 million in 2021 to RMB 6,146.2 million in 2022, driven by growth in pharmaceuticals and radiation therapy equipment[47] - Gross profit rose by 8.4% from RMB 3,241.9 million in 2021 to RMB 3,514.7 million in 2022, with a gross margin decrease from 63.0% to 57.2%[48] - Net profit increased by 12.1% from RMB 673.0 million in 2021 to RMB 754.6 million in 2022[54] Assets and Liabilities - Total assets as of December 31, 2022, were RMB 11,685,540,000, up from RMB 10,473,968,000 in 2021[9] - Total liabilities increased to RMB 5,132,257,000 from RMB 4,442,580,000 in 2021[9] - Current assets increased by 12.9% from RMB 6,656.8 million in 2021 to RMB 7,512.7 million in 2022, with a current asset net value growth of 31.3% to RMB 3,524.9 million[56] - The total trade and other receivables as of December 31, 2022, amounted to RMB 3,647.8 million, with a provision for bad debts of RMB 195.8 million[59] - The total trade and other payables as of December 31, 2022, were RMB 3,759.0 million, reflecting the company's obligations[60] Research and Development - Research and development investment intensity exceeded 10% for the first time, indicating a strong commitment to innovation[11] - The company has multiple radiopharmaceuticals in various stages of research and development, including [18F] sodium fluoride injection, which has completed clinical trials and submitted for market registration[24] - The company has applied for 174 patents during the reporting period, with 134 patents granted, including one foreign patent, marking a breakthrough in overseas patent authorization[28] - The company has established multiple research centers focusing on various fields, including radiopharmaceuticals and in vitro diagnostic technologies[29] - The company has a strong focus on innovation, with 678 valid patents as of December 31, 2022, including 105 invention patents[28] Market and Business Development - The company generated 63.83% of its revenue and 79.55% of its gross profit from the pharmaceutical segment, indicating a strong focus on nuclear medicine[10] - The market demand for nuclear technology applications is expected to continue growing, providing significant development opportunities for the company[10] - The company is actively promoting the market for strontium-89 injection products and has initiated projects with 65 hospitals to accelerate the application of nuclear medicine[23] - The company is focused on innovation in the fields of medical isotopes, radioactive drugs, and high-end nuclear medical equipment, with plans to create a national-level technology center and increase R&D investment[36] - The company plans to achieve new highs in operating revenue and net profit in 2023, driven by favorable policies and increased attention to the medical isotope industry[36] Corporate Governance - The company has adopted the corporate governance code as a benchmark for its governance practices, ensuring high ethical standards in operations[75] - The board consists of 11 members, including 3 executive directors and 4 independent non-executive directors, ensuring a balanced composition for effective decision-making[78] - The company has implemented an annual independence assessment mechanism for its board, ensuring effective governance and independent judgment[84] - The board has reviewed and revised corporate governance policies and internal controls during the reporting period, enhancing operational efficiency[87] - The company has established a clear process for the appointment and re-election of directors, ensuring transparency and accountability[86] Employee and Talent Management - The group employed 3,366 employees, an increase from 3,120 employees as of December 31, 2021[72] - Employee costs for the year ended December 31, 2022, were approximately RMB 795.7 million, compared to RMB 663.4 million for the year ended December 31, 2021, reflecting a year-over-year increase of 19.9%[72] - The company has a talent pool of 538 R&D personnel, including 12 national-level talents and 14 provincial-level talents, focusing on production technology optimization and new product development[32] - The company has committed to providing training for employees to enhance their skills and support their career development[72] Shareholder and Financial Policies - The company has no predetermined dividend payout ratio, and dividends are proposed based on financial conditions and board recommendations[121] - The company reported a total cash dividend of RMB 140,968,868.43 for the fiscal year ending December 31, 2022, subject to shareholder approval[143] - The company will withhold a 10% corporate income tax on dividends distributed to non-resident corporate shareholders[144] - The company has established a shareholder communication policy to address shareholder concerns effectively[121] Strategic Partnerships and Collaborations - The company plans to leverage its collaboration with China National Nuclear Corporation to enhance its capabilities in isotope and radiopharmaceutical applications[10] - The company has signed a collaboration agreement with FutureChem for the exclusive rights to develop, produce, and market [18F] Florastamin injection in China, with clinical trial applications submitted and accepted[25] - The company has established research cooperation with several prestigious institutions and universities, enhancing academic exchange and talent cultivation[32] Risks and Compliance - The company faces operational risks including domestic and international economic conditions, credit policies, and regulatory changes[142] - The company has established a comprehensive strategy to address potential uncertainties and risks in its operations[142] - The company emphasizes compliance with tax regulations regarding dividend distributions to H-share holders[145] Continuing Connected Transactions - The company has ongoing agreements with China National Nuclear Corporation for leasing, supply, and consulting services, all expiring on December 31, 2023, with potential for renewal[189][191][192] - Independent non-executive directors reviewed the continuing connected transactions and confirmed they were conducted in the ordinary course of business and on normal commercial terms[200] - The proposed annual caps for the continuing connected transactions are deemed fair and reasonable, aligning with the overall interests of the company and its shareholders[200]